1243154-05-3

Basic information

• Product Name: C₂₉H₄₃N₇O₇
• Synonyms: C₂₉H₄₃N₇O₇
• CAS NO: 1243154-05-3
• Molecular Weight: 601.703
• Mol File: 1243154-05-3.mol

Chemical Properties

• CAS DataBase Reference: C₂₉H₄₃N₇O₇(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₉H₄₃N₇O₇(1243154-05-3)
• EPA Substance Registry System: C₂₉H₄₃N₇O₇(1243154-05-3)

Safety Data

• Hazardous Substances Data: 1243154-05-3(Hazardous Substances Data)

Upstream product

• 312760-07-9 1-(2,3-bis(tert-butoxycarbonyl)guanidino)prop-2-yne 
• 332882-82-3 tert-butyl N-[amino(tert-butoxycarbonylamino)methylene]carbamate 
• 1243153-98-1 (3R)-(2-azido-acetylamino)-3-phenyl-propionic acid t-butyl ester 
• 332882-82-3 1,3-bis(t-butoxycarbonyl)guanidine 

Downstream Products

• 1243153-87-8 (R)-3-[2-(4-guanidinomethyl[1,2,3]triazol-1-yl)acetylamino]-3-phenylpropionic acid hydrochloride 
• 1243239-09-9 (R)-3-[2-(4-guanidinomethyl[1,2,3]triazol-1-yl)acetylamino]-3-phenylpropionic acid 

Relevant articles and documents

1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS

The present invention refers to the field of chemical compounds bearing a 1,2,3-triazole ring of formula (I) and possessing guanidino and carboxylic groups or their isosteres, their preparation by Cu-catalyzed “click-chemistry”, and medical-diagnostic use in pathologies where angiogenesis is altered, for example pathologic conditions of tumor origin, tumor metastasis, osteoporosis, and rheumatoid arthritis.

1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS

The present invention refers to the field of chemical compounds bearing a 1,2,3-triazole ring of formula (I) and possessing guanidino and carboxylic groups or their isosteres, their preparation by Cu-catalyzed "click-chemistry", and medical - diagnostic use in pathologies where angiogenesis is altered, for example pathologic conditions of tumor origin, tumor metastasis, osteoporosis, and rheumatoid arthritis.

Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis

A click chemistry approach was applied for the discovery of triazole-based arginine-glycine-aspartate (RGD) mimetics by Cu(I)-catalyzed 1,3-dipolar alkyne-azide coupling reaction, which showed binding affinity properties toward αvβ3/αvβ5 integrins. Biological assays showed compound 18 capable of binding αvβ3 integrin with nanomolar affinity according to a two-sites model, and molecular modeling studies revealed a peculiar π-stacking interaction between the triazole ring and Tyr178 side chain. Accordingly, compound 18 inhibited the adhesion of integrin-expressing human melanoma cells to RGD-containing proteins of the extracellular matrix, such as vitronectin, fibronectin, and osteopontin, and also angiogenesis in in vitro and in vivo experimental models. The relevant biological effects exerted by compound 18 suggest its potential application as an antiangiogenic agent in the diagnosis and therapy of tumors where αvβ3 integrin expression is up-regulated.